Today: 11 June 2026
Citigroup stock faces Trump’s 10% credit-card rate cap as Citi earnings near
11 January 2026
2 mins read

Citigroup stock faces Trump’s 10% credit-card rate cap as Citi earnings near

New York, Jan 11, 2026, 15:51 EST — Market closed

  • Citi shares closed Friday roughly 0.6% higher, at $121.32.
  • Starting Jan. 20, Trump proposed capping credit-card interest rates at 10% for one year.
  • Citi will release its fourth-quarter earnings on Jan. 14, following inflation data set to drop a day before.

Shares of Citigroup Inc entered the new week following U.S. President Donald Trump’s call for a one-year cap on credit-card interest rates at 10%, accusing lenders of “ripping off” consumers. Citi’s stock closed Friday up roughly 0.6% at $121.32. Reuters

Timing is key. A hard cap could squeeze interest income for card lenders right as investors shift focus from macroeconomic chatter to bank earnings, with Citi standing out as a major player. The bank plans to release its fourth-quarter results around 8 a.m. ET Wednesday, followed by a webcast and call at 11 a.m. ET.

Bank stocks are priced for strong earnings, with investors banking on capital-markets revenue holding steady late last year. Barron’s notes that Citigroup is now trading at its highest valuation since 2008.

A 10% cap would be well below the rates most cardholders currently face. Barron’s reported the average credit-card rate at about 19.65%, noting that a 10% limit would mark the lowest level since at least 1994. Companies with significant card exposure—JPMorgan Chase, Capital One, and American Express—are also in the spotlight.

Information remains limited, complicating matters for traders. According to The Washington Post, major banks have warned that imposing a cap might restrict credit availability. Hedge fund manager Bill Ackman called the move a “mistake,” warning it could lead to card cancellations among higher-risk borrowers.

Rates are another key factor. Friday’s U.S. jobs report revealed unemployment dropped to 4.4%, while annual wage growth climbed to 3.8%. This bolsters the view that the Federal Reserve will hold rates steady at its Jan. 27-28 meeting. “All roads lead to the unemployment rate … it should douse the Fed’s recent urgency to backstop a weakening labor market,” said Olu Sonola, head of U.S. economic research at Fitch Ratings. Reuters

Investors will digest fresh inflation figures before Citi posts its results. The Labor Department’s CPI report for December 2025 drops Tuesday at 8:30 a.m. ET. This release often moves Treasury yields and, consequently, bank stock values.

Citi’s report will have investors zeroing in on card credit trends and any shifts in the bank’s assessment of consumer stress. They’ll also scrutinize net interest income — the gap between earnings on loans and costs of funding — plus expense control and any signals on capital returns.

But outcomes vary widely. The card-rate cap might end up as little more than political posturing, or it could gain traction, pushing lenders to tighten credit, raise fees, or cut back on lines for riskier borrowers. On another front, a hotter CPI figure or a cautious earnings forecast could weigh on stocks that have already seen gains.

Citi traders are zeroing in on Tuesday’s inflation report and Wednesday’s earnings call as the next major triggers. Any clear signals from Washington on card rates before Jan. 20 could drive the market’s next shift.

Stock Market Today

  • How to Invest Indirectly in SpaceX Before IPO Through ETFs
    June 11, 2026, 10:46 AM EDT. Investors can gain indirect exposure to SpaceX ahead of its IPO via ETFs like ERShares Private-Public Crossover ETF (XOVR) and AGIX. These funds use special purpose vehicles (SPVs)-legal entities holding SpaceX shares-to navigate SEC rules allowing up to 15% allocation in illiquid private companies. XOVR holds about 13.2% exposure to SpaceX through SPVs, while AGIX combines SPV investments with a small direct stake. Investors should note these ETFs are thematic portfolios with broad tech focuses and relatively high expense ratios. Direct public investment remains available only after SpaceX's Nasdaq debut at ticker SPCX on June 12, priced around $135, targeting a $1.75-$2 trillion valuation.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Tencent Holdings stock: buyback keeps pressure on bears as AI bottleneck warning hits tape
Previous Story

Tencent Holdings stock: buyback keeps pressure on bears as AI bottleneck warning hits tape

UiPath stock: CEO share sale filing puts PATH in focus ahead of a busy week
Next Story

UiPath stock: CEO share sale filing puts PATH in focus ahead of a busy week

Go toTop